Navigation Links
Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Date:1/29/2008

- $161.5 million in cash at year end; no equity financings expected in 2008 - Significant progress in lead lysosomal disease programs to continue in 2008; latest data for all programs to be presented at ACMG meeting in March - Expansion of research and development investment in pharmacological chaperone platform planned for targets beyond lysosomal diseases in 2008

CRANBURY, N.J., Jan. 29 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD), a biopharmaceutical company developing small molecule, orally- active pharmacological chaperones for the treatment of human genetic diseases, today announced financial results for the fourth quarter and full year of 2007. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.53 per share ($0.48 per share on a non-GAAP basis) for the three months ended December 31, 2007. For the year ended December 31, 2007, on a GAAP basis, the net loss attributable to common stockholders was $3.14 per share ($2.80 per share on a non-GAAP basis). As of December 31, 2007, cash, cash equivalents, and marketable securities totaled $161.5 million. Amicus Chief Financial Officer James Dentzer noted that: "We have ended 2007 in a strong financial position. We have several years of cash on hand, and this is further enhanced by the cost sharing and expected milestones from our partnership with Shire Human Genetic Therapies. As a result, we do not expect to raise cash from any equity financings in 2008."

In November 2007, Amicus entered into a strategic collaboration with Shire Human Genetic Therapies, a business unit of Shire plc, to jointly develop Amicus' three lead pharmacological
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Amicus Therapeutics Announces Positive Results From Phase 2 Clinical Trials of Amigal(TM) for Fabry Disease
2. Amicus Therapeutics to Host R&D Day
3. Amicus Therapeutics to Present at the Lazard Capital Markets Fourth Annual Healthcare Conference
4. Meredith Martin Addy Named Chair of AIPLAs Amicus Committee
5. Amicus Therapeutics Announces Third Quarter 2007 Financial Results
6. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotech & Medtech 2007 Conference
7. Allos Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
8. Cell Therapeutics, Inc. (CTI) Shareholders Authorize Share Increase at Special Meeting of Shareholders
9. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
10. Nile Therapeutics Appoints Gregory W. Schafer to Board of Directors
11. Arno Therapeutics Completes License Agreements for the Exclusive Rights to Novel, Targeted Cancer Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2013)... Toronto, Canada (PRWEB) May 23, 2013 ... subjects, it is critical to adhere to principles ... protection (HSP). , Esteemed speaker Dr. Jeremy Lim, ... the audience: , ,     Understand the ... Clinical Practice (GCP) and additional regulations for the ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 ... ancestry tracing for people of African descent, today ... product offering. For people of all races, myDNAmix ... from five distinct populations: Indigenous Americas (Native American), ... India Subcontinent. , Originally launched in ...
(Date:5/23/2013)... (PRWEB) May 23, 2013 Watlow®, ... of complete thermal systems, recently introduced its new ... years of experience in designing and manufacturing industrial ... of products to serve diverse customer needs. , ... featured at the beginning of the book. These ...
(Date:5/22/2013)... Oven Industries announces the new 5R1-1400 ... via a PC through the TTL level UART Communication ... inches square can deliver up to 15 AMPS of ... solid state relay. Operator safety is achieved with 1KV ... and sensor input. Specifications: Input Voltage 85 to ...
Breaking Biology Technology:Adhering to Good Clinical Practice, New Webinar Hosted by Xtalks 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 2AfricanAncestry.com Rolls Out Improved MyDNAMix Admixture Test for People of all Races; Enhancements Increase Accuracy in Estimation of Ancestral Makeup 3Watlow Introduces Its New Industrial Heater Catalog 2New AC Temperature Controller Announced by Oven Industries 2
... 3 Albert Liou, Corporate Vice,President and General ... PRXL ), a leading global,biopharmaceutical services provider, will ... Cost and Efficiency Savings in Running Clinical,Trials?" at ... and,Exhibition, to be held November 4 - 7, ...
... Altogen Biosystems (http://www.altogen.com ),announced launch of novel ... facilities for animal testing. Transfection is,one of the ... RNA molecules,into cells and tissues. This technique makes ... a gene or a small interfering RNA (siRNA),into ...
... N.J., Nov. 3 Arno Therapeutics,Inc. (OTC Bulletin Board: ... announced that Dr. Roger G. Berlin,Chief Executive Officer of ... Healthcare Conference on Monday, November 10, 2008 at 2:00 ... York Palace Hotel in New York City. Dr.,Berlin will ...
Cached Biology Technology:PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress 2PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress 3PAREXEL Expert to Address Key Aspects of Conducting Clinical Trials in China at 7th Annual Partnerships in Clinical Trials Congress 4Altogen Biosystems Launches New Nanoparticle-based In Vivo Transfection Reagent 2Arno Therapeutics to Present at the Rodman & Renshaw 10th Annual Healthcare Conference 2
(Date:5/22/2013)... 22, 2013. Plastic additives known as phthalates (pronounced ... They turn up in flooring, plastic cups, beach ... Centers for Disease Control and Preventionthe bodies of ... come under increasing scrutiny. A growing collection of ... leech from packaging and mix with food) may ...
(Date:5/21/2013)... the nation,s land and water resources could likely support ... 25 billion gallons of algae-based fuel a year in ... , The findings come from an in-depth look at ... significant amounts of algae in large, specially built shallow ... issue of Environmental Science and Technology , published ...
(Date:5/21/2013)... Cancers of all types become most deadly when they ... has reached this stage, it becomes very difficult for ... can develop. Now, researchers at the University of Missouri ... target lymphoma tumor cells wherever they may be in ... in the MU College of Veterinary Medicine, says being ...
Breaking Biology News(10 mins):Study links chemicals widely found in plastics and processed food to elevated blood pressure in children and teens 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 2Going green: Nation equipped to grow serious amounts of pond scum for fuel 3Going green: Nation equipped to grow serious amounts of pond scum for fuel 4MU researchers develop radioactive nanoparticles that target cancer cells 2
... of radiation based on verified scientific facts will be available ... The official kick-off meeting of the Community project ULICE ... Union is supporting with nearly 10 million euros, was held ... Therapy of the Heidelberg University Hospital. This consortium consists of ...
... the U.S. population is afflicted with an autoimmune ... chronic and require life-long care. Moreover, different autoimmune ... are caused by disruptions in common biological pathways. ... pathways, The Jackson Laboratory has published "Pathways to ...
... at UT Southwestern Medical Center have eliminated non-small cell ... drug called BEZ235 in combination with low-dose radiation. ... Cancer Research , UT Southwestern researchers found that ... of tumor cells with otherwise nontoxic radiation, the drug ...
Cached Biology News:Patients in Europe benefit from new radiation therapy 2Patients in Europe benefit from new radiation therapy 3UT Southwestern researchers use drug-radiation combo to eradicate lung cancer 2
Sheep polyclonal to Melatonin ( Abpromise for all tested applications). Antigen: Melatonin Tg conjugate....
Goat anti-PITPN Class: Antibody Product Group: Miscellaneous Antibody...
COMING SOON: Anti-Mouse CD205 (DEC-205),Clone NLDC-145, mAb...
Anti-MT3-MMP Membrane-Type Metalloproteinase-3; propeptide domain; rabbit host...
Biology Products: